Last Updated : April 18, 2024
Details
FilesGeneric Name:
bimekizumab
Project Status:
Active
Therapeutic Area:
Ankylosing spondylitis
Manufacturer:
UCB Canada Inc.
Call for patient/clinician input open:
Brand Name:
Bimzelx
Project Line:
Reimbursement Review
Project Number:
SR0809-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
The treatment of adult patients with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
The treatment of adult patients with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | August 30, 2023 |
|---|---|
| Call for patient/clinician input closed | October 24, 2023 |
| Clarification: - Patient input submission received from Arthritis Consumer Experts, Canadian Spondyloarthritis Association (CSA),Canadian Arthritis Patient Alliance (CAPA),Arthritis Society Canada (ASC) and Creaky Joints (CJ) | |
| Submission received | October 19, 2023 |
| Submission accepted | November 02, 2023 |
| Review initiated | November 03, 2023 |
| Draft CADTH review report(s) provided to sponsor for comment | January 30, 2024 |
| Deadline for sponsors comments | February 08, 2024 |
| CADTH review report(s) and responses to comments provided to sponsor | March 14, 2024 |
| Expert committee meeting (initial) | March 27, 2024 |
| Draft recommendation issued to sponsor | April 10, 2024 |
| Draft recommendation posted for stakeholder feedback | April 18, 2024 |
| End of feedback period | May 03, 2024 |
Files
Last Updated : April 18, 2024